Department of Biology, Institute of Integrative Cell Biology and Physiology (IIZP), University of Münster, Schloßplatz 5, 48149, Münster, Germany.
Department of Cardiovascular Medicine, Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, 48149, Münster, Germany.
Sci Rep. 2024 Aug 24;14(1):19673. doi: 10.1038/s41598-024-69748-y.
Several human diseases, including cancer and neurodegeneration, are associated with excessive mitochondrial fragmentation. In this context, mitochondrial division inhibitor (Mdivi-1) has been tested as a therapeutic to block the fission-related protein dynamin-like protein-1 (Drp1). Recent studies suggest that Mdivi-1 interferes with mitochondrial bioenergetics and complex I function. Here we show that the molecular mechanism of Mdivi-1 is based on inhibition of complex I at the IQ site. This leads to the destabilization of complex I, impairs the assembly of N- and Q-respirasomes, and is associated with increased ROS production and reduced efficiency of ATP generation. Second, the calcium homeostasis of cells is impaired, which for example affects the electrical activity of neurons. Given the results presented here, a potential therapeutic application of Mdivi-1 is challenging because of its potential impact on synaptic activity. Similar to the Complex I inhibitor rotenone, Mdivi-1 may lead to neurodegenerative effects in the long term.
几种人类疾病,包括癌症和神经退行性疾病,都与线粒体过度碎片化有关。在这种情况下,线粒体分裂抑制剂(Mdivi-1)已被测试作为一种治疗方法来阻断与分裂相关的蛋白 dynamin-like protein-1(Drp1)。最近的研究表明,Mdivi-1 会干扰线粒体生物能学和复合物 I 功能。在这里,我们表明 Mdivi-1 的分子机制基于在 IQ 位点抑制复合物 I。这导致复合物 I 的不稳定性,损害 N-和 Q-呼吸体的组装,并与增加的 ROS 产生和降低的 ATP 生成效率相关。其次,细胞的钙稳态受到损害,例如影响神经元的电活动。鉴于这里提出的结果,由于其对突触活动的潜在影响,Mdivi-1 的潜在治疗应用具有挑战性。与复合物 I 抑制剂鱼藤酮类似,Mdivi-1 可能会导致长期的神经退行性效应。